1.
Current Challenges in Cancer Treatment
by Zugazagoitia, Jon, MD, PhD
Clinical therapeutics, 2016, Vol.38 (7), p.1551-1566
2.
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
by Shaverdian, Narek, MD
The lancet oncology, 2017, Vol.18 (7), p.895-903
3.
HER2-positive breast cancer
by Loibl, Sibylle, Prof
The Lancet (British edition), 2016, Vol.389 (10087), p.2415-2429
4.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lu...
by West, Howard
The lancet oncology, 2019-07, Vol.20 (7), p.924-937
5.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACT...
by Kang, Yoon-Koo
The Lancet (British edition), 2017-12-02, Vol.390 (10111), p.2461-2471
6.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, n...
by Herbst, Roy S, Prof
The lancet oncology, 2019, Vol.20 (8), p.1109-1123
7.
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
by Younes, Anas, Prof
The lancet oncology, 2016, Vol.17 (9), p.1283-1294
8.
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
by Shu, Catherine A
The lancet oncology, 2020-06, Vol.21 (6), p.786-795
9.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
10.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
by Provencio, Mariano
The lancet oncology, 2020-11, Vol.21 (11), p.1413-1422
11.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 s...
by Balar, Arjun V
The lancet oncology, 2017-11, Vol.18 (11), p.1483-1492
12.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
by Overman, Michael J
The lancet oncology, 2017-09, Vol.18 (9), p.1182-1191
13.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label,...
by Paz-Ares, Luis
The lancet oncology, 2021-02, Vol.22 (2), p.198-211
14.
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0...
by Coleman, Robert L, Prof
The lancet oncology, 2017, Vol.18 (6), p.779-791
15.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
by El-Khoueiry, Anthony B, Dr
The Lancet (British edition), 2017, Vol.389 (10088), p.2492-2502
16.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
by Makker, Vicky
The lancet oncology, 2019-05, Vol.20 (5), p.711-718
17.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, control...
by Eng, Cathy
The lancet oncology, 2019-06, Vol.20 (6), p.849-861
18.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 stu...
by Kim, Sung-Bae
The lancet oncology, 2020-04, Vol.21 (4), p.519-530
19.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-la...
by Marabelle, Aurélien
The lancet oncology, 2020-10, Vol.21 (10), p.1353-1365
20.
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an inter...
by Thuss-Patience, Peter C, MD
The lancet oncology, 2017, Vol.18 (5), p.640-653
